From a clinical trial concept perspective, correlative studies with ongoing rhabdomyosarcoma clinical trials are informative: the class I/IV HDAC inhibitor mocetinostat, has shown activity in combination with vinorelbine in an ongoing phase I clinical trial of patients with refractory or recurrent RMS21. The gene discussed is HDAC9; the disease is rhabdomyosarcoma.